116 related articles for article (PubMed ID: 36098856)
1. Delineation of a T-cell receptor CDR3-cancer mutanome aromaticity factor, assessable via blood samples, that facilitates the establishment of survival distinctions in bladder cancer.
Waweru JW; Mwangi KW; Barker VR; Gozlan EC; Yeagley M; Blanck G; Makokha FW
J Cancer Res Clin Oncol; 2023 Jul; 149(8):4359-4366. PubMed ID: 36098856
[TBL] [Abstract][Full Text] [Related]
2. Immune receptor CDR3 chemical features that preserve sequence information are highly efficient in reflecting survival distinctions: A pan-cancer analysis.
Mcbreairty BE; Chobrutskiy BI; Chobrutskiy A; Gozlan EC; Diaz MJ; Blanck G
Biomed Rep; 2022 Aug; 17(2):68. PubMed ID: 35815190
[TBL] [Abstract][Full Text] [Related]
3. T-cell receptor-α CDR3 domain chemical features correlate with survival rates in bladder cancer.
Chobrutskiy BI; Zaman S; Diviney A; Mihyu MM; Blanck G
J Cancer Res Clin Oncol; 2019 Mar; 145(3):615-623. PubMed ID: 30539280
[TBL] [Abstract][Full Text] [Related]
4. A scoring system for the electrostatic complementarities of T-cell receptors and cancer-mutant amino acids: multi-cancer analyses of associated survival rates.
Chobrutskiy BI; Yeagley M; Diviney A; Zaman S; Gozlan EC; Tipping P; Koohestani DM; Roca AM; Blanck G
Immunology; 2020 Apr; 159(4):373-383. PubMed ID: 31821535
[TBL] [Abstract][Full Text] [Related]
5. Blood-based T cell receptor anti-viral CDR3s are associated with worse overall survival for neuroblastoma.
Kacsoh DB; Diaz MJ; Gozlan EC; Sahoo A; Song JJ; Yeagley M; Chobrutskiy A; Chobrutskiy BI; Blanck G
J Cancer Res Clin Oncol; 2023 Oct; 149(13):12047-12056. PubMed ID: 37421457
[TBL] [Abstract][Full Text] [Related]
6. Electrostatic Complementarity of T-Cell Receptor-Alpha CDR3 Domains and Mutant Amino Acids Is Associated with Better Survival Rates for Sarcomas.
Yeagley M; Chobrutskiy BI; Gozlan EC; Medikonda N; Patel DN; Falasiri S; Callahan BM; Huda T; Blanck G
Pediatr Hematol Oncol; 2021 Apr; 38(3):251-264. PubMed ID: 33616477
[TBL] [Abstract][Full Text] [Related]
7. High-throughput, sliding-window algorithm for assessing chemical complementarity between immune receptor CDR3 domains and cancer mutant peptides: TRG-PIK3CA interactions and breast cancer.
Chobrutskiy BI; Chobrutskiy A; Zaman S; Yeagley M; Huda TI; Blanck G
Mol Immunol; 2021 Jul; 135():247-253. PubMed ID: 33933816
[TBL] [Abstract][Full Text] [Related]
8. TRB CDR3-cancer testis antigen chemical complementarity scoring for identifying productive immune responses in renal cell carcinoma.
Hudock TR; Barker VR; Manley BJ; Chobrutskiy A; Chobrutskiy BI; Diaz MJ; Song JJ; Blanck G
Cancer Biomark; 2023; 38(1):103-110. PubMed ID: 37545223
[TBL] [Abstract][Full Text] [Related]
9. Chemical complementarity between immune receptor CDR3s and candidate cancer antigens correlating with reduced survival: evidence for outcome mitigation with corticosteroid treatments.
Patel AR; Patel DN; Tu YN; Yeagley M; Chobrutskiy A; Chobrutskiy BI; Blanck G
J Biomol Struct Dyn; 2023 Jul; 41(10):4632-4640. PubMed ID: 35538689
[TBL] [Abstract][Full Text] [Related]
10. IGL CDR3 Hydropathy and Antigen Chemical Complementarity Associated with Greater Disease-Free Survival in Lung Adenocarcinoma: Implications for Gender Disparities.
Charkowick SV; Huda TI; Patel DN; Yeagley M; Arturo JF; Cios KJ; Gozlan EC; Chobrutskiy A; Chobrutskiy BI; Blanck G
Biochem Genet; 2024 Feb; 62(1):530-546. PubMed ID: 37392243
[TBL] [Abstract][Full Text] [Related]
11. TCR CDR3-antigen chemical complementarity associated with poor ovarian cancer outcomes: A vestigial immune response to early cancer antigens?
Barker VR; Varkhedi M; Patel DN; Hsiang M; Chobrutskiy A; Chobrutskiy BI; Blanck G
Am J Reprod Immunol; 2023 Jan; 89(1):e13639. PubMed ID: 36317868
[TBL] [Abstract][Full Text] [Related]
12. Chemical features of melanoma tumor resident TRG CDR3s associated with better survival probabilities.
Agnila DRL; Huda TI; Eakins RA; Patel DN; Hsiang M; Chobrutskiy A; Chobrutskiy BI; Blanck G
Melanoma Res; 2023 Aug; 33(4):275-282. PubMed ID: 37222076
[TBL] [Abstract][Full Text] [Related]
13. TRB CDR3 chemical complementarity with HBV epitopes correlates with increased hepatocellular carcinoma, disease-free survival.
Song JJ; Chobrutskiy A; Chobrutskiy BI; Cios KJ; Huda TI; Eakins RA; Diaz MJ; Blanck G
J Med Virol; 2023 Aug; 95(8):e29043. PubMed ID: 37621059
[TBL] [Abstract][Full Text] [Related]
14. Chemical complementarity between immune receptors and cancer mutants, independent of antigen presentation protein binding, is associated with increased survival rates.
Hsiang M; Chobrutskiy BI; Diaz M; Huda TI; Creadore S; Zaman S; Cios KJ; Gozlan EC; Blanck G
Transl Oncol; 2021 Jun; 14(6):101069. PubMed ID: 33780706
[TBL] [Abstract][Full Text] [Related]
15. Immunogenomics of colorectal adenocarcinoma: Survival distinctions represented by immune receptor, CDR3 chemical features and high expression of BTN gene family members.
Diaz MJ; Chobrutskiy BI; Zaman S; Blanck G
Cancer Treat Res Commun; 2020; 24():100196. PubMed ID: 32769037
[TBL] [Abstract][Full Text] [Related]
16. CDR3 analysis of TCR Vβ repertoire of CD8⁺ T cells from chickens infected with Eimeria maxima.
Ren C; Yin G; Qin M; Suo J; Lv Q; Xie L; Wang Y; Huang X; Chen Y; Liu X; Suo X
Exp Parasitol; 2014 Aug; 143():1-4. PubMed ID: 24801021
[TBL] [Abstract][Full Text] [Related]
17. Chemical complementarity between tumor resident, T-cell receptor CDR3s and MAGEA3/6 correlates with increased melanoma survival: Potential relevance to MAGE vaccine auto-reactivity.
Eakins RA; Chobrutskiy A; Teer JK; Patel DN; Hsiang M; Huda TI; Zaman S; Sexton WJ; Coppola D; Falasiri S; Blanck G; Chobrutskiy BI
Mol Immunol; 2022 Oct; 150():58-66. PubMed ID: 35987136
[TBL] [Abstract][Full Text] [Related]
18. Tracking global changes induced in the CD4 T-cell receptor repertoire by immunization with a complex antigen using short stretches of CDR3 protein sequence.
Thomas N; Best K; Cinelli M; Reich-Zeliger S; Gal H; Shifrut E; Madi A; Friedman N; Shawe-Taylor J; Chain B
Bioinformatics; 2014 Nov; 30(22):3181-8. PubMed ID: 25095879
[TBL] [Abstract][Full Text] [Related]
19. Chemical Complementarity of Tumor Resident, Adaptive Immune Receptor CDR3s and Previously Defined Hepatitis C Virus Epitopes Correlates with Improved Outcomes in Hepatocellular Carcinoma.
Song JJ; Chobrutskiy A; Chobrutskiy BI; Cios KJ; Huda TI; Eakins RA; Diaz MJ; Blanck G
Viral Immunol; 2023 Dec; 36(10):669-677. PubMed ID: 38052065
[TBL] [Abstract][Full Text] [Related]
20. Analysis of the CDR3 length repertoire and the diversity of TCR alpha chain in human peripheral blood T lymphocytes.
Yao XS; Diao Y; Sun WB; Luo JM; Qin M; Tang XY
Cell Mol Immunol; 2007 Jun; 4(3):215-20. PubMed ID: 17601376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]